London, 14 July 2022: The announcement follows the MHRA’s consultation on the future regulation of medical devices in the UK which asked healthcare professionals and institutions, businesses, trade associations and patients for their views on the classification and identification of devices, manufacturers and suppliers.
80 per cent of respondents advocated the use of GS1 data standards such as GTINs to uniquely identify, track, and trace medical devices across healthcare supply chains from manufacture right through to the point of care.
As a result, the MHRA will authorise GS1 as an issuing entity for UDI, supporting the government’s strategy for strengthening regulation, improving patient safety and providing consistency for manufacturers and healthcare providers alike.
The MHRA’s new UDI system will align with existing international regulations to provide a globally harmonised framework for medical device identification. This will significantly reduce the risk of clinical error and allow for swift and effective product recalls in the event of potentially harmful devices entering the market.
Based on the consultation’s recommendations, the government will:
- Require all manufacturers of medical devices to assign Unique Device Identifiers such as GS1 Global Trade Item Numbers (GTINs) to all products
- Require all reusable devices to bear a scannable UDI carrier such as barcode or Radio Frequency Identification (RFID) tag
- Issue essential requirements and guidance for Basic UDI device identifiers (BUDI-DI), to ensure the rationale for, and value of, collecting this information is clear
The government also intends to use data standards to uniquely identify manufacturers, UK Responsible Persons, importers and distributors, who will all be required to register with the MHRA. The consultation offered three options – DUNS, GS1 and the MHRA’s own identifier – and more than one third of respondents favoured the use of GS1 standards.
The MHRA will collaborate with stakeholders to gradually refine legislation and ensure that their ambitious, transformational programme of reform allows both industry and healthcare providers to adapt to future changes.
Glen Hodgson, head of healthcare at GS1 UK said, “More than 90 per cent of medical device manufacturers are already using GTINs as the primary identifier in the United States’ FDA Global Unique Device Identification Database. Couple this with the fact that GS1 is already authorised as an issuing entity for many other international medical device regulations, we are pleased to see the MHRA align on this matter."
“We will continue to support our members with the adoption of GS1 standards to ensure consistency and standardisation across the board. It is a key part of ensuring traceability and more importantly, patient safety.”
- ENDS -
NOTES TO EDITORS
For further information or requests for interviews, contact Alex Cox: 07464946769; alexander.cox@gs1uk.org.
About GS1 UK
GS1 UK is one of 116 neutral and independent GS1 organisations operating worldwide.
Whether online, in store or in a hospital, the common language of GS1 standards is helping our community of over 58,000 organisations to uniquely identify, describe and track anything, creating greater trust in data for everyone.
Our standards have the power to deliver change now and in the future by driving efficiency in the supply chain, and transparency in the wider society, through initiatives such as patient safety programmes and deposit return schemes.
From product barcodes to patient wristbands, we harness the power of GS1 standards to transform the way people work and live.